Novartis sees Saudi Arabia as promising market for producing its cancer drugs

Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore––Saudi Arabia.

The Swiss drugmaker has signed off on a memorandum of understanding with Sudair Pharma for a technology transfer that would allow the Saudi Arabian company to produce a number of “innovative” cancer drugs in the kingdom, the Arab News reports.